Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Relapsed or Refractory Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT06845241
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fu zhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hosptital, Zhengzhou, Henan, China
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis Patients
- Interventions
- Drug: ICP-488 TabletsDrug: ICP-488 Placebo
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06842199
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳Shanghai Skin Disease Hospital skin Disease of tongji University, Shanghai, Shanghai, China
🇨🇳Taiyuan Central Hospital, Taiyuan, Shanxi, China
ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: ICP-332 TabletsDrug: ICP-332 Placebo Tablets
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 552
- Registration Number
- NCT06775860
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The Second Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Capital Medical University Affiliated Beijing Chaoyang Hospital, Beijing, Beijing, China
ICP-248 in Combination with Azacitidine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia(AML) or Previously Treated Relapsed/Refractory Subjects with Acute Myelogenous Leukemia(R/R AML).
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT06656494
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- DLBCL
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 244
- Registration Number
- NCT06521255
- Locations
- 🇨🇳
Xinjiang Medical University Affiliated Cancer Hospital, Urumqi, China
🇨🇳Henan Cancer Hospital, Zhengzhou, China
🇨🇳Beijing Hospital, Beijing, China
ICP-248 in Combination with Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 226
- Registration Number
- NCT06378138
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital (The First Affiliated Hospital of University of Science and Technology of China), Hefei, Anhui, China
🇨🇳Gansu Provincial People's Hospital, Lanzhou, Gansu, China
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis
- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- Drug: ICP-488 PlaceboDrug: ICP-488 Tablets
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 129
- Registration Number
- NCT06109818
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Chengdu Second People's Hospital, Chengdu, Sichuan, China
Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma
- Conditions
- Relapsed/Refractory Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 324
- Registration Number
- NCT06082102
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Auhui, China
🇨🇳Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia
- Conditions
- Chronic Primary Immune Thrombocytopenia (ITP)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 195
- Registration Number
- NCT06004856
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing CHAO-YANG Hospital Capital Medcal University, Beijing, Beijing, China
Study of ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
- Conditions
- Primary Central Nervous System Tumors Harboring NTRK FusionAdvanced Solid Tumors Harboring NTRK Fusion
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT05745623
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China